+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pharmacovigilance Market By Type, By Service Provider (In-house, Contract Outsourcing), By Clinical Trial Phase, and By End-User (Hospitals, Research Organisations, Others), Forecasts To 2027

  • ID: 5351604
  • Report
  • July 2020
  • Region: Global
  • 150 pages
  • Reports and Data
Increasing drug approvals, and rising number of ADR (Adverse Drug Reaction) reporting are key factors driving market revenue growth.

Market Size - USD 6,255.2 Million in 2020, Market Growth - CAGR of 10.8%, Market Trends - Rising trend of outsourcing services for pharmacovigilance by players and hospitals.

The global pharmacovigilance market size is expected to reach USD 14.32 Billion in 2028, and register a CAGR of 10.8% during the forecast period. Increasing use of pharmacovigilance (PV or PhV) to ensure drug safety and prevention of adverse effects of drugs is a major factor expected to drive growth of the global pharmacovigilance market. For instance, as per studies conducted by the WHO (World Health Organization), in various developed countries, around 5% of hospitalized patients were admitted in hospitals due to ADR. Additionally, between 6% - 10% of in-patients could experience serious ADR during hospitalization.

Some Key Findings From the Report:
  • Among the clinical trial phase segments, the phase IV segment accounted for the largest revenue share of 76.3% in 2020.
  • Among the end use segments, the hospitals segment accounted for the largest revenue share in 2020. Hospital pharmacists are of utmost significance in ADR (Adverse Drug Reaction Reporting), as the majority of the serious adverse drug events happen in hospitals due to higher patient footfall in hospitals, and these ADRs are responsible for a considerable proportion of hospital admissions.
  • The Asia Pacific market size was USD 1,313.6 Million in 2020, due to increasing healthcare infrastructure, rising prevalence of various chronic diseases, and need for clinical trials for commercializing drugs.
  • Key players profiled in the report include Accenture, Cognizant, ArisGlobal, IBM Corporation, IQVIA, BoClinica Inc., Laboratory Corporation of America Holdings, Linical Accelovance, Capgemini, and ITClinical. The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand market footprint.
  • In 2019, Accenture PLC, which is an Ireland-based consulting company, partnered with a Belgium-based biopharmaceutical company, for building a safety solution based on Accenture’s INTIENT™ pharmacovigilance to expedite processing of individual patient safety case reports.
For the purpose of this report, the global pharmacovigilance market is segmented on the basis of type, service provider, clinical trial phase, end use, and region:

Type Outlook
  • Spontaneous Reporting
  • Intensified Adverse Drug Reaction (ADR) Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • Electronic Health Record (HER) Mining
Service Provider Outlook
  • In-House
  • Contract Outsourcing
Clinical Trial Phase Outlook
  • Pre-Clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
End Use Outlook
  • Hospitals
  • Research Organizations
  • Others
Region Outlook
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Benelux
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Rest of Latin America
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa
Reasons to Buy the Report
  • A robust analysis and estimation of the Pharmacovigilance Market with four levels of quality check - in-house database, expert interviews, governmental regulation, and a forecast specifically done through time series analysis
  • A holistic competitive landscape of the all the major players in the Pharmacovigilance Market. The report covers their market shares, strategic initiatives, new product launches, R&D expenditure, M&As, Joint ventures, expansionary plans, product wise metric space analysis and key developments
  • Go-to-market strategies specifically formulated in line with location analysis which takes into the factors such as government regulations, supplier mapping, supply chain obstacles, and feedback from local vendors
  • Most deep dive segmental bifurcation available currently in the market. Our stellar methodology helps us understand the overall gamut of the supply chain and will help you explain the current market dynamics
  • Special focus given on vendor landscape, supplier portfolio, customer mapping, production capacity, and yearly capacity utilization
Note: Product cover images may vary from those shown
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique

Chapter 2. Executive Summary
2.1. Summary Snapshot, 2019-2027

Chapter 3. Indicative Metrics

Chapter 4. Pharmacovigilance Segmentation & Impact Analysis
4.1. Pharmacovigilance Material Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
4.2.2.1. Growing prevalence of adverse drug reactions and toxicity
4.2.2.2. Rise in drug consumption and development rates
4.2.2.3. Growing trend towards outsourcing pharmacovigilance
4.2.3. Market restraints analysis
4.2.3.1. Dearth of skilled professionals
4.3. Technological Insights
4.4. Regulatory Framework
4.5. ETOP Analysis
4.6. Porter’s Five Forces Analysis
4.7. Competitive Metric Space Analysis
4.8. Price trend Analysis
4.9. Customer Mapping
4.10. Covid-19 Impact Analysis
4.11. Global Recession Influence

Chapter 5. Pharmacovigilance Market Type Insights & Trends
5.1. Type dynamics & Market Share, 2020 & 2027
5.2. Spontaneous Reporting
5.2.1. Market estimates and forecast, 2017 2027 (USD Million)
5.2.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
5.3. Intensified Adverse Drug Reaction (ADR) Reporting
5.3.1. Market estimates and forecast, 2017 2027 (USD Million)
5.3.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
5.4. Targeted Spontaneous Reporting
5.4.1. Market estimates and forecast, 2017 2027 (USD Million)
5.4.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
5.5. Cohort Event Monitoring
5.5.1. Market estimates and forecast, 2017 2027 (USD Million)
5.5.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
5.6. Electronic Health Record (EHR) Mining
5.6.1. Market estimates and forecast, 2017 2027 (USD Million)
5.6.2. Market estimates and forecast, by region, 2017 2027 (USD Million)

Chapter 6. Pharmacovigilance Market By Service Provider Insights & Trends
6.1. Service Provider Dynamics & Market Share, 2020 & 2027
6.2. In-House
6.2.1. Market estimates and forecast, 2017 2027 (USD Million)
6.2.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
6.3. Contract Outsourcing
6.3.1. Market estimates and forecast, 2017 2027 (USD Million)
6.3.2. Market estimates and forecast, by region, 2017 2027 (USD Million)

Chapter 7. Pharmacovigilance Market By Clinical Trial Phase Insights & Trends
7.1. Clinical Trial Phase Dynamics & Market Share, 2020 & 2027
7.2. Pre-Clinical
7.2.1. Market estimates and forecast, 2017 2027 (USD Million)
7.2.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
7.3. Phase I
7.3.1. Market estimates and forecast, 2017 2027 (USD Million)
7.3.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
7.4. Phase II
7.4.1. Market estimates and forecast, 2017 2027 (USD Million)
7.4.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
7.5. Phase III
7.5.1. Market estimates and forecast, 2017 2027 (USD Million)
7.5.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
7.6. Phase IV
7.6.1. Market estimates and forecast, 2017 2027 (USD Million)
7.6.2. Market estimates and forecast, by region, 2017 2027 (USD Million)

Chapter 8. Pharmacovigilance Market By End-Users Insights & Trends
8.1. End-Users Dynamics & Market Share, 2020 & 2027
8.2. Hospitals
8.2.1. Market estimates and forecast, 2017 2027 (USD Million)
8.2.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
8.3. Research Organizations
8.3.1. Market estimates and forecast, 2017 2027 (USD Million)
8.3.2. Market estimates and forecast, by region, 2017 2027 (USD Million)
8.4. Others
8.4.1. Market estimates and forecast, 2017 2027 (USD Million)
8.4.2. Market estimates and forecast, by region, 2017 2027 (USD Million)

Chapter 9. Pharmacovigilance Market Regional Outlook
9.1. Pharmacovigilance Market share by region, 2020 & 2027
9.2. North America
9.2.1. Covid-19 Impact Analysis, 2020-2021
9.2.2. Global Recession Influence, 2020-2021
9.2.3. North America Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.2.4. North America Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.2.5. North America Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.2.6. North America Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.2.7. North America Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.2.8. U.S.
9.2.8.1. U.S. Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.2.8.2. U.S. Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.2.8.3. U.S. Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.2.8.4. U.S. Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.2.8.5. U.S. Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.3. Europe
9.3.1. Covid-19 Impact Analysis, 2020-2021
9.3.2. Global Recession Influence, 2020-2021
9.3.3. Europe Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.3.4. Europe Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.3.5. Europe Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.3.6. Europe Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.3.7. Europe Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.3.8. U.K.
9.3.8.1. U.K. Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.3.8.2. U.K. Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.3.8.3. U.K. Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.3.8.4. U.K. Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.3.8.5. U.K. Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.3.9. France
9.3.9.1. France Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.3.9.2. France Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.3.9.3. France Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.3.9.4. France Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.3.9.5. France Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.4. Asia-Pacific
9.4.1. Covid-19 Impact Analysis, 2020-2021
9.4.2. Global Recession Influence, 2020-2021
9.4.3. Asia-Pacific Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.4.4. Asia Pacific Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.4.5. Asia Pacific Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.4.6. Asia Pacific Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.4.7. Asia Pacific Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.4.8. China
9.4.8.1. China Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.4.8.2. China Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.4.8.3. China Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.4.8.4. China Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.4.8.5. China Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.4.9. India
9.4.9.1. India Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.4.9.2. India Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.4.9.3. India Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.4.9.4. India Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.4.9.5. India Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.4.10. Japan
9.4.10.1. Japan Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.4.10.2. Japan Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.4.10.3. Japan Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.4.10.4. Japan Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.4.10.5. Japan Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.5. Middle East and Africa
9.5.1. Covid-19 Impact Analysis, 2020-2021
9.5.2. Global Recession Influence, 2020-2021
9.5.3. Middle East and Africa Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.5.4. Middle East & Africa Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.5.5. Middle East & Africa Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.5.6. Middle East & Africa Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.5.7. Middle East & Africa Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.6. Latin America
9.6.1. Covid-19 Impact Analysis, 2020-2021
9.6.2. Global Recession Influence, 2020-2021
9.6.3. Latin America Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.6.4. Latin America Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.6.5. Latin America Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.6.6. Latin America Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.6.7. Latin America Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)
9.6.8. Brazil
9.6.8.1. Brazil Pharmacovigilance Market estimates and forecast, 2017 2027, (USD Million)
9.6.8.2. Brazil Pharmacovigilance Market estimates and forecast By Type, 2017 -2027, (USD Million)
9.6.8.3. Brazil Pharmacovigilance Market estimates and forecast by Service Provider, 2017 -2027, (USD Million)
9.6.8.4. Brazil Pharmacovigilance Market estimates and forecast by Clinical Trial Phase, 2017 -2027, (USD Million)
9.6.8.5. Brazil Pharmacovigilance Market estimates and forecast by End-Users, 2017 -2027, (USD Million)

Chapter 10. Competitive Landscape
10.1. Market Revenue Share by Manufacturers
10.2. Manufacturing Cost Breakdown Analysis
10.3. Mergers & Acquisitions
10.4. Market positioning
10.5. Strategy Benchmarking
10.6. Customer Mapping
10.7. Vendor Landscape

Chapter 11. Company Profiles
11.1. Accenture
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Technology Insights
11.1.4. Strategic Initiatives
11.2. Cognizant
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Technology Insights
11.2.4. Strategic Initiatives
11.3. ArisGlobal
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Technology Insights
11.3.4. Strategic Initiatives
11.4. IBM Corporation
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Technology Insights
11.4.4. Strategic Initiatives
11.5. IQVIA
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Technology Insights
11.5.4. Strategic Initiatives
11.6. BoClinica Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Technology Insights
11.6.4. Strategic Initiatives
11.7. Laboratory Corporation of America Holdings
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Technology Insights
11.7.4. Strategic Initiatives
11.8. Linical Accelovance
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Technology Insights
11.8.4. Strategic Initiatives
11.9. Capgemini
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Technology Insights
11.9.4. Strategic Initiatives
11.10. ITClinical
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Technology Insights
11.10.4. Strategic Initiatives
Note: Product cover images may vary from those shown
Adroll
adroll